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1 Introduction
This report is a supplement to a data set from a clinical study performed at Hvidovre University Hospital,
Denmark as a part of the DIACON (Diabetes in Control) project in 2009-2010. The DIACON project is
an interdisciplinary team situated in Denmark with both clinicians and scientist involved in the project.
The aim of the DIACON project is to develop automatic treatment methods for type 1 diabetes and
thereby improve the quality of life for the patients. The ultimate goal is to obtain fully closed loop
control of the blood glucose level. This is known as the artificial pancreas and consists of continuous
subcutaneous insulin infusion (CSII) from a pump, a continuous glucose monitor (CGM) obtaining the
blood glucose level and finally, a control algorithm regulating the insulin pump based on feed back from
the CGM. The controller determines the optimal amount of insulin to keep the blood glucose in the target
range. An illustration of the components of an artificial pancreas is seen in Figure 1.
In the development of control algorithms for an artificial pancreas, virtual type 1 diabetes patients are
a useful tool for pre-clinical testing and verification. The advantages are several: acceleration of the
development process, lower costs, and the possibility of testing extreme treatment strategies without
having to deal with the ethical aspects.
One of the purposes of the DIACON project is to develop a robust and reliable model of the insulin-blood
glucose dynamical system. To be able to do this we needed a data set including observations of the system
in type 1 diabetes patients.
Since the insulin-blood glucose system is a very complex system affected by many different factors such
as meals, physical exercise and changes in stress level etc., the study had to be quite controlled. Further,
a previous ambulant study had shown that out clinic data is too noise corrupted and unreliable due
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Figure 1: Illustration of the artificial pancreas.
to unknown disturbances and incorrect reportings by the involved patients. For these reasons the data
collection was performed in clinic and designed to mirror the every day life of type 1 diabetes patients.
Meals, insulin boluses, and physical exercise were included as factors (controlled inputs) since they are
believed to be have the greatest effect on the blood glucose level. By separating the occurrence of the
factors and initiate them in changing order a total of 24 different sequences were constructed. The
obtained data set is extensive and hence use full for many different modeling purposes.
The present report can be seen as an introduction to the study design and a guide to the data files
including all data. It is intended for students, researchers or clinicians who wish to use the data for
modeling purposes or get insight in to the insulin-blood glucose dynamics.
Furthermore, the majority of the results of this study has been published in the paper ”Effects of Everyday
Life Events on Glucose, Insulin, and Glucagon Dynamics in Continuous Subcutaneous Insulin Infusion-
Treated Type 1 Diabetes: Collection of Clinical Data for Glucose Modeling” in the journal ”Diabetes
Technology and Therapeutics”, see [2] for details.
The following sections will explain the study design in detail including subject statistics followed by a
presentation of all the data observed and a guide to the data files following this report.
2 Description of the study design
As mentioned in the introduction, to collect data suitable for advanced modelling of type 1 diabetes is
it advantageuos to do a controlled in-clinic study to avoid disturbances by uncontrolled factors. This
section describes the study design.
2.1 Study design
The clinical study was designed from the theory of classical design of experiments. The basis was a
factorial design with three main factors, each investigated on two levels. The factors and the defined
levels are described in detail in section 2.2. The study consisted of 24 different sequences (study days) in
which the three factors were combined differently.
In every day life the factors affecting the blood glucose level are often confounded, e.g., a meal is usually
accompanied by a insulin bolus. Hence it can be difficult to estimate the true effect of each factor.
To avoid problems with unidentifiability due to confounding factors, the occurrence of the events was
separated in time by 150 minutes. A study day included three different events in total.
The combination and order of event types is seen in Figure 2. The first event was always a meal since
the patients had been fastening for at least 10 hours before start. The second and third event was either
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Figure 2: Schematic overview of the study design. In total the study included 24 different sequences. T is study
time.
a bolus, exercise or a snack. Prior to the first event was a stabilization period from 8AM to 10AM (T=0
min) to bring the blood glucose level in the normal range. Likewise, was the last event (T=300 min)
followed by a stabilization period to make the patient ready to leave the clinic.
2.2 Event types
In this study the three events investigated was: Meal including fast-acting carbohydrates, exercise on a
treadmill and insulin boluses. Each event type was studied at two levels. Additionally, some study days
included a liquid snack. A description of the levels is seen in table 1.
The meal was either given with half the meal bolus or with no bolus at all. The size of the meal bolus was
determined from the subjects weight and personal insulin-to-carbohydrate ratio (ICR). ICR is defined as
the amount of carbohydrate in milligrams one unit of insulin can counterbalance. The energy composition
of the meal was 52% carbohydrates, 18%protein and 30% fat. It included simple carbohydrates form white
bread, ham, cheese, margarine, marmalade, milk and juice. The snack was a protein drink with an energy
composition of 89% carbohydrates and 11% protein. The size of the meal and snack was determined from
the body weight as seen in Table 1.
Exercise was separated in a mild and moderate level, the former defined as 50% of interval between resting
heart rate and maximum heart rate and the latter as 75%. An insulin bolus was separated into a small
and large bolus, a small bolus was defined to lower blood glucose by 3 mmol/L based on the personal
insulin sensitivity factor (ISF) and a large bolus was defined to lower blood glucose by 6 mmol/L based
on personal ISF. ISF is defined as point drop in plasma glucose (mmol/L) per unit of insulin.
Table 1: Description of event types
Event type Levels Description
Meal Unbolused Solid food with drink. 1 g of CHO/kg body
weight. No meal bolus.
Underbolused Solid food with drink. 1 g of CHO/kg body
weight. 50% of the insulin bolus matching the
meal CHO content based on personal ICR.
Exercise Mild 0.5 x (maximum HR - resting HR) + resting
HR.
Moderate 0.7 x (maximum HR - resting HR) + resting
HR.
Bolus Small Insulin bolus estimated to lower blood glucose
level by 3 mmol/L based on personal ISF.
Large Insulin bolus estimated to lower blood glucose
level by 6 mmol/L based on personal ISF.
Snack NA Liquid. 0.4 g of CHO/kg of body weight.
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2.3 Data collection
During the study day blood glucose level was analyzed every ten minutes. Insulin level was analyzed
every ten minutes 30 minutes after an event otherwise every 30 minutes. Additionally, glucagon, cortisol,
growth hormone, and epinephrine and norepinephrine levels were analyzed according to the same scheme
as insulin. The CGM recorded the sensor glucose level every 5 minutes. The Actiheart recorded activity
and heart rate every minute.
3 Description of patients and equipment
This section present physiological details about the patients and details regarding the equipment used
for monitoring and analysis.
3.1 Patients
Twelve type 1 diabetes patients participated in the study. They were all recruited from the diabetes
clinic at Hvidovre Hospital. All were treated with insulin aspart (Novo Nordisk, BagsvA˜¦rd, Denmark)
using a pump (Paradigm 522/722 from Medtronic, Northridge, CA) for at least six months before the
first visit. The patient characteristics are shown in table 2.
Table 2: Patient Characteristics
Female sex 75%
Age 34.3±9.1 years
Body mass index 25.1±4.3 kg/m2
Diabetes duration 16.5±10.2 years
C-peptide 0.097±0.078 nmol/L
Hemoglobin A1c 6.7±0.4%
Total daily insulin 0.63±0.11 U/kg/day
3.2 Equipment for blood analysis
The blood samples drawn during the study where analyzed for different hormone concentrations and
blood glucose concentration. This section describes the methods and equipment used for these analysis.
Blood glucose was analyzed with gold standard equipment (YSI2300 STAT Plus, Yellow Springs Instru-
ments, Yellow Springs, OH).
Insulin aspart was analyzed with a specific immunoassay using the LOCI-technology at Novo Nordisk
A/S, Ma˚løv, Denmark.
The glucagon analysis was made with a pancreas specific glucagon assay with a low detection limit at the
Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen,
Copenhagen, Denmark. The glucagon assay was directed against the C-terminal of the glucagon molecule
(antibody code no. 4305) and therefore measures glucagon of mainly pancreatic origin
Cortisol was analyzed with Solid-phase chemiluminiscense competitiv immunometric assay and growth
hormone was analyzed with Solid-phase two-site chemiluminiscense immunometric assay both on Im-
mulite 2000 (Siemens Healthcare Diagnostics) at Department of clinical biochemistry, Hvidovre Hospital,
Denmark.
For the plasma catecholamine extraction procedure the The concentration of epinephrine and nore-
pinephrine was determined by HPLC with electrochemical detection (Pcat extraction kit part no: 45-0141,
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Thermo Fisher Scientific, California, USA). The column was a Prodigy 3u ODS (3) C18 (2 mm x 100
mm, particle size 3 µm, phenomenex). The mobile phase consisted of 55 mM sodium acetate, 1 mM
octanesulfonic acid, 0.1 mM Na2EDTA and 8% Acetonitrile, adjusted to pH 3.2 with 0.1M acetic acid,
and was degassed using an on-line degasser. Twenty µl of the samples were injected and the flow rate
was 0.15 mL/min. The electrochemical detection was accomplished using an amperometric detector (An-
tec Decade from Antec, Leiden, The Netherlands) with a glassy carbon electrode set at 0.8 V, with an
Ag/AgCl as reference electrode.
3.3 Activity monitor and continuous glucose monitor
To monitor the activity level of the patients, the Actiheart (CamNtech Ltd., Cambridge,UK) was used.
The Actiheart monitors heart rate and activity from an accelerometer. During the study the patients also
wore a CGM (Paradigm Real-Time, Medtronic) observing the glucose level in the subcutaneous layer.
4 Description of data files
For each study day a .csv file with all the data exits. All types of outputs and covariates are included.
The time resolution is in minutes. Furthermore, an info file and comments file are included for each
sequence.
Some of the data files includes missing observations. Look in the comments file for information about
missing observations and other discrepancies between the planned sequence and what was performed.
In the table below all the input and outputs are stated in the order they appear in the data file. First
column is a time vector which is followed by four inputs vectors corresponding to carbohydrates, insulin
delivery, IV glucose administration and prescribed exercise level determined from the beats per minute
(BPM). Hereafter blood glucose (YSI) and sensor glucose (CGM) values are stated followed by insulin
plasma concentration and the remaining hormones stated in section 2.3. Finally, data and information
from the Actiheart are listed.
The content of the info file can be seen in table 4. It contains information about the study: date, and
sequence no., and information about the patient, e.g., age, weight, resting heart rate (HR), and basal
insulin rate settings for the pump.
The comments files include a time vector corresponding to the one in the data files and the comments
from the physician in charge of the study. They also include blood pressure observations obtained during
the study day.
The data files are named with a number representing the participant and the letter ’a’ or ’b’ indicating
whether it is the first or the second study day for that participant. E.i. the data file for participant
no. 3’s second event is named 03b data.csv. The info and comments files are named 03b info.csv and
03b comments.csv respectively.
4.1 Conversion of units
In glucose modelling and diabetes research, different units are used for blood glucose and sensor glucose
level. The most often used unit for insulin is units. In table 5 is the different conversion factors for
glucose and insulin stated. For the plots presented later in this report, the unit for cortisol was changed
from nmol/L to ng/mL. This conversion is also included in the table.
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Table 3: Data file content
Variable Unit Description
TT [min] Trial time
CHO [g] Carbohydrate intake
Iin [U] Insulin delivery from the pump
Gin [g] I.V. Glucose delivery
EX [BPM] Prescribed exercise level
YSI [mmol/L] Plasma glucose level
CGM [mmol/L] Subcutanoues glucose level
Iout [pM] Insulin concentration in plasma
GG [pM] Glucagon concentration in plasma
CS [nmol/L] Cortisol concentration in plasma
GH [ng/mL] Growth hormone concentration in plasma
AL [ng/mL] Adrenaline concentration in plasma
NL [ng/mL] Noradrenaline concentration in plasma
ACT [Counts] Activity level
CL BPM [BPM] Observed heart rate (cleaned)
Raw BPM [BPM] Observed heart rate (raw)
OK/Rec [-] Index indicating whether the BPM recording is properly
recorded (OK) or had to be recovered (Rec)
ECG (µV ) [µV ] Eccocardiogram observations used to calculate ACT
Lt s [s] Amount of lots seconds in the current minute in the Actiheart
J/ep [Joule] Joules per epoch
J/ep/kg [Joule] Joules per epoch per kilo body weight
5 Plots of data
This section presents plots of the entire data set. In Table 6 an overview of the entire study is presented.
Each plot presents the specific sequence and timing and size of inputs: Meals, insulin boluses and intra-
venously administrated glucose. Furthermore, all the analyzed observations are plotted, e.g., YSI, CGM,
Insulin aspart, glucagon, heart rate, activity, norepinephrine, epinephrine, cortisol and growth hormone.
The title of the plots is participant no. and a or b referring to the first or second study day for that
participant. Note that for participant no. 01 they are named 01b and 01c since we performed a pilot
study on this participant which is not included. Participant no. 9 was excluded from the study due to
pregnancy and no data exists from this participant. An additional participant was included instead (no.
13).
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Table 4: Info file content
Variable Description
Date Date of the study day
Sequence no. 1:24
Patient ID Initials and date of birth
Patient trial no. States the patients no. of visit.
Age Age in years
Sex M/F
Weight Body weight in kg
Height Height in meters
Norm. ICR The patient’s normal insulin-to-carbohydrate ratio
Norm. ISF The patient’s normal insulin sensitivity factor
Basal insulin rate Time interval: Basal rate
Target BG The target blood glucose
Resting HR Resting heart rate
Maximum HR Maximum heart rate
Actiheart Device A or B
Sensor placement States the placement of the sensor on the body
Pump placement States the placement of the pump on the body
Diabetes debut Year of diabetes debut
Medication List of the patient’s medication (if any)
Table 5: Conversion of units
Glucose [1] 1 mmol/L 18.0182 mg/dL
Insulin[1] 6 pM 1 mU/L
Cortisol [1] 1 nmol/L 2.759 ng/mL
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Table 6: Overview of the clinical DIACON study 2009-2010
Patient # Event 1 Event 2 Event 3 Short code
01 b Meal w/o bolus Moderate exercise Large bolus 0bMOeLb
01 c Meal w ½bolus Moderate exercise Small bolus ½bMOeSb
02 a Meal w ½bolus Small bolus Mild exercise ½bSbMIe
02 b Meal w ½bolus Mild exercise Small bolus ½bMIeSb
03 a Meal w/o bolus Large bolus Mild exercise 0bLbMIe
03 b Meal w ½bolus Large bolus Moderate exercise ½bLbMOe
04 a Meal w ½bolus Small bolus Snack ½bSbSn
04 b Meal w ½bolus Mild exercise Large bolus ½bMIeLb
05 a Meal w ½bolus Moderate exercise Snack ½bMOeSn
05 b Meal w/o bolus Small bolus Snack 0bSbSn
06 a Meal w ½bolus Large bolus Mild exercise ½bLbMIe
06 b Meal w ½bolus Moderate exercise Large bolus ½bMOeLb
07 a Meal w/o bolus Mild exercise Small bolus 0bMIeSb
07 b Meal w/o bolus Moderate exercise Small bolus 0bMOeSb
08 a Meal w/o bolus Mild exercise Snack 0bMIeSn
08 b Meal w/o bolus Large bolus Moderate exercise 0bLbMOe
10 a Meal w ½bolus Moderate exercise Small bolus ½bMOeSb
10 b Meal w ½bolus Mild exercise Snack ½bMIeSn
11 a Meal w ½bolus Large bolus Snack ½bLbSn
11 b Meal w/o bolus Mild exercise Large bolus 0bMIeLb
12 a Meal w/o bolus Small bolus Moderate exercise 0bSbMOe
12 b Meal w/o bolus Moderate exercise Snack 0bMOeSn
13 a Meal w/o bolus Small bolus Mild exercise 0bSbMIe
13 b Meal w/o bolus Large bolus Snack 0bLbSn
The code in the last column is combined of the three event during the study day.
0b corresponds to a meal w/o bolus and ½b corresponds to a meal w/ half bolus.
Lb corresponds to at large bolus. Sb corresponds to a small bolus. MOe corresponds to
moderate exercise. MIe corresponds to mild exercise. Sn corresponds to a snack.
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Figure 3: Results from trial 01b. Note that the S.C. insulin is above zero according to table ll at all times even
though it is hard to see.
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Figure 4: Results from trial 01c. Note that the S.C. insulin is above zero according to the info file.
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Figure 5: Results from trial 02a. Note that the S.C. insulin is above zero according to the info file.
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Figure 6: Results from trial 02b. Note that the S.C. insulin is above zero according to the info file.
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Figure 7: Results from trial 03a. Note that the S.C. insulin is above zero according to the info file.
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Figure 8: Results from trial 03b. Note that the S.C. insulin is above zero according to the info file.
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Figure 9: Results from trial 04a. Note that the S.C. insulin is above zero according to the info file.
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Figure 10: Results from trial 04b. Note that the S.C. insulin is above zero according to the info file.
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Figure 11: Results from trial 05a. Note that the S.C. insulin is above zero according to table ll at all times even
though it is hard to see.
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Figure 12: Results from trial 05b. Note that the S.C. insulin is above zero according to table ll at all times even
though it is hard to see.
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Figure 13: Results from trial 06a. Note that the S.C. insulin is above zero according to the info file.
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Figure 14: Results from trial 06b. Note that the S.C. insulin is above zero according to the info file.
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Figure 15: Results from trial 07a. Note that the S.C. insulin is above zero according to the info file.
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Figure 16: Results from trial 07b. Note that the S.C. insulin is above zero according to table ll at all times even
though it is hard to see.
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Figure 17: Results from trial 08a. Note that the S.C. insulin is above zero according to the info file.
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Figure 18: Results from trial 08b. Note that the S.C. insulin is above zero according to the info file.
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Figure 19: Results from trial 10a. Note that the S.C. insulin is above zero according to the info file.
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Figure 20: Results from trial 10b. Note that the S.C. insulin is above zero according to the info file.
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Figure 21: Results from trial 11a. Note that the S.C. insulin is above zero according to the info file.
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Figure 22: Results from trial 11b. Note that the S.C. insulin is above zero according to the info file.
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Figure 23: Results from trial 12a. Note that the S.C. insulin is above zero according to the info file.
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Figure 24: Results from trial 12b. Note that the S.C. insulin is above zero according to the info file.
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Figure 25: Results from trial 13a. Note that the S.C. insulin is above zero according to the info file.
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Figure 26: Results from trial 13b. Note that the S.C. insulin is above zero according to the info file.
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